Results 101 to 110 of about 240,433 (353)
Targeting of TP53-independent cell cycle checkpoints overcomes FOLFOX resistance in Metastatic Colorectal Cancer [PDF]
, 2021 Corina Behrenbruch +23 more
openalex +1 more source
Hepatology, EarlyView., 2022 Steatotic HCC can be diagnosed by MRI and forms a pro‐tumor immune microenvironment with high expression of PD‐L1, M2 polarization of macrophages and activation of CAFs, which may be a good target for combined immunotherapy. Abstract Background and Aims Immunotherapy has become the standard‐of‐care treatment for hepatocellular carcinoma (HCC), but its ...
Hiroki Murai +29 more
wiley +1 more source
Turkish Journal of Hematology, 2017 Objective: Chronic lymphocytic leukemia (CLL) is the most common lymphoproliferative disease in adults. The aim of this study is to find out if the extent of proliferation centers or the immunohistochemical expression of p53 is related to disease ...
İbrahim Kulaç +4 more
doaj +1 more source
The paradox of cancer genes in non-malignant conditions: implications for precision medicine. [PDF]
, 2020 Next-generation sequencing has enabled patient selection for targeted drugs, some of which have shown remarkable efficacy in cancers that have the cognate molecular signatures.
Adashek, Jacob J +3 more
core
Mutant NPM1 in Acute Myeloid Leukemia Initiation and Maintenance
Aging and Cancer, EarlyView.NPM1 mutations drive acute myeloid leukemia by acting as neomorphic transcriptional regulators that cooperate with Menin–MLL and XPO1 to sustain HOX/MEIS1 expression and block differentiation. Targeting these mutant‐specific transcriptional dependencies provides a rational therapeutic strategy for NPM1‐mutated AML.
Yanan Jiang +3 more
wiley +1 more source
Proteogenomic characterization of cholangiocarcinoma
Hepatology, EarlyView., 2022 Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng +18 more
wiley +1 more source
Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients
Cancer Management and Research, 2020 Yan Qin,1,* Shiyu Jiang,1,* Peng Liu,1 Jianliang Yang,1 Sheng Yang,1 Xiaohui He,1 Shengyu Zhou,1 Lin Gui,1 Jing Lin,2 Xinhua Du,3 Yuting Yi,3 Yan Sun,1 Yuankai Shi1 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center
Qin Y +12 more
doaj
A role for p53 in telomere protection
Molecular & Cellular Oncology, 2017 Telomeres cap the ends of chromosomes and are crucial for genome stability. The p53 protein (TP53) is a vital tumor suppressor, activating the transcription of numerous genes in response to cell stress.
Stephen Tutton, Paul M. Lieberman
doaj +1 more source